TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects

NCT04168723 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: MD1003
DRUG: Moxifloxacin 400mg
DRUG: Placebo for MD1003
DRUG: Placebo for moxifloxacin

Sponsor

MedDay Pharmaceuticals SA

Collaborators

[object Object]
[object Object]